Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.80 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 5/20 | 0.56 |
| ▸ | CTSK | P43235 | 5/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSV | O60911 | 1/20 | 0.52 |
| ▸ | PLAT | P00750 | 1/20 | 0.52 |
| ▸ | CTSH | P09668 | 1/20 | 0.52 |
| ▸ | CASP14 | P31944 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20938665 | 0.88 | RAB9A (0.75) | RAB9APDE4APTGS2CTSSCTSK | |
| SCHEMBL13326008 | 0.88 | RAB9A (0.75) | RAB9APDE4APTGS2CTSSCTSK | |
| SCHEMBL14600703 | 0.88 | RAB9A (0.75) | RAB9APDE4APTGS2CTSSCTSK | |
| SCHEMBL19053287 | 0.85 | SMN1; SMN2 (0.69) | RAB9ACTSSCTSKCTSL | |
| SCHEMBL13326006 | 0.85 | RAB9A (0.74) | RAB9APDE4APTGS2CTSSCTSK | |
| SCHEMBL18557113 | 0.82 | PDE4A (0.82) | RAB9APDE4APTGS2CTSSCTSK | |
| SCHEMBL18557112 | 0.82 | PDE4A (0.82) | RAB9APDE4APTGS2CTSSCTSK | |
| SCHEMBL18760598 | 0.82 | PDE4A (0.82) | RAB9APDE4APTGS2CTSSCTSK | |
| SCHEMBL20402878 | 0.82 | PDE4A (0.82) | RAB9APDE4APTGS2CTSSCTSK | |
| SCHEMBL11794474 | 0.82 | PDE4A (0.82) | RAB9APDE4APTGS2CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | claimed |
| US-20070072856-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-03-29 | — | — | US | claimed |
| US-7064125-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2006-06-20 | — | — | US | claimed |
| US-20060035896-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| US-20040162288-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-08-19 | — | — | US | claimed |
| WO-2002036578-A9 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2004-04-22 | — | — | WO | claimed |
| US-20030100557-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2003-05-29 | — | — | US | claimed |
| US-20020103195-A1 | LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS,INC. | 2002-08-01 | — | — | US | claimed |
| WO-2002036578-A2 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | claimed |
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7608620-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7199238-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPUETICS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20070072856-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-7064125-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060035896-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| US-20040162288-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-08-19 | — | — | US | disclosed |
| WO-2002036578-A9 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20030100557-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020103195-A1 | LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS,INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002036578-A2 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035896-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | RAB9A 4247/4885PDE4A 644/4885PTGS2 1905/4885 |
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | LPCAT3, LPCAT1, PLAAT2 | RAB9A 4000/4885PDE4A 394/4885PTGS2 2457/4885 |
| US-20020103195-A1 | LPAAT-B inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | RAB9A 3602/4885PDE4A 580/4885PTGS2 2228/4885 |
| US-20070072856-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | RAB9A 4000/4885PDE4A 394/4885PTGS2 2457/4885 |
| US-20040162288-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | RAB9A 4051/4885PDE4A 400/4885PTGS2 2398/4885 |
| US-20030100557-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | RAB9A 4051/4885PDE4A 400/4885PTGS2 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.